Latest Breaking News On - யூரோப் பின்தொடரவும் - Page 3 : comparemela.com

Bharat Biotech not allowed to conduct simultaneous Phase I, II trials for its intranasal COVID-19 vaccine The SEC has reportedly refused to consider Bharat Biotech’s request and said it wants the Indian vaccine maker to first conduct the phase I trials and submit the immunogenicity data before moving on to the next stage. Bharat Biotech has claimed that the non-invasive, single-dose vaccine will be far easier to administer. Bharat Biotech has not been allowed to conduct simultaneous phase I and phase II trials for its nasal COVID-19 vaccine candidate, reported CNBC-TV18 on January 19. Sources say SEC did not consider the request of Bharat Biotech to conduct both Phase 1 & 2 trials simultaneously for its nasal #vaccine candidate. SEC wants co to first conduct phase 1 & submit immunogenicity data before seeking approval for phase 2 pic.twitter.com/qNg4kOpGhH

United statesKrishna ellaWashington university school of medicineCentral drugs standard control organizationExpert committeeBharat biotechSubject expert committeeWashington university schoolEurope followIntranasal vaccineIntranasal covid 19 vaccineIntranasal coronavirus vaccineBharat biotechs covid 19 vaccineBharat biotechs intransal covid 19 vaccineBharat biotech coronavirus vaccineBharat biotech covid vaccine